- Home
- INTS vs COEP Comparison
INTS vs COEP Comparison
Compare INTS & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- COEP
- Stock Information
- Founded
- INTS 2012
- COEP 2017
- Country
- INTS United States
- COEP United States
- Employees
- INTS N/A
- COEP N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INTS Health Care
- COEP Health Care
- Exchange
- INTS Nasdaq
- COEP Nasdaq
- Market Cap
- INTS 33.4M
- COEP 32.4M
- IPO Year
- INTS 2023
- COEP N/A
- Fundamental
- Price
- INTS $2.23
- COEP $10.52
- Analyst Decision
- INTS Strong Buy
- COEP
- Analyst Count
- INTS 3
- COEP 0
- Target Price
- INTS $8.50
- COEP N/A
- AVG Volume (30 Days)
- INTS 26.6K
- COEP 109.2K
- Earning Date
- INTS 03-13-2025
- COEP 03-25-2025
- Dividend Yield
- INTS N/A
- COEP N/A
- EPS Growth
- INTS N/A
- COEP N/A
- EPS
- INTS N/A
- COEP N/A
- Revenue
- INTS N/A
- COEP N/A
- Revenue This Year
- INTS N/A
- COEP N/A
- Revenue Next Year
- INTS N/A
- COEP N/A
- P/E Ratio
- INTS N/A
- COEP N/A
- Revenue Growth
- INTS N/A
- COEP N/A
- 52 Week Low
- INTS $1.50
- COEP $2.31
- 52 Week High
- INTS $5.94
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- INTS 49.26
- COEP 48.65
- Support Level
- INTS $1.84
- COEP $9.27
- Resistance Level
- INTS $2.27
- COEP $12.95
- Average True Range (ATR)
- INTS 0.28
- COEP 1.59
- MACD
- INTS -0.01
- COEP -0.33
- Stochastic Oscillator
- INTS 56.36
- COEP 38.56
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.